CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 85 enrolled
Drug / intervention
Rifabutin +1 moredrug
Likely dose
Rifabutin 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00646776
NCT00646776Phase 1Completed
CompareCT.gov

Study to Evaluate the Exposure of Rifabutin Administered in an Alternate Regimen in Combination With Atazanavir and Ritonavir Healthy Subjects

Bristol-Myers Squibb·interventional·Posted Mar 31, 2008·Updated Jan 31, 2013

In Brief

A Phase 1 clinical trial evaluating Rifabutin and Rifabutin + Atazanavir + Ritonavir for Antivirals/HIV. Completed, enrolled 85 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the exposure of rifabutin (RIB) when administered with atazanavir and ritonavir (ATV/RTV)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAntivirals/HIV
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 31, 2008
Enrollment StartApr 1, 2008
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.3 years ago

Interventions

Rifabutindrug

Capsule, Oral, 150 mg, once daily, 11 Days

Rifabutin + Atazanavir + Ritonavirdrug

Capsules, Oral, 18 Days Rifabutin (150 mg, 2x/wk) Atazanavir (300 mg, once daily) Ritonavir (100 mg, once daily)